218 related articles for article (PubMed ID: 25807425)
1. Polymyalgia rheumatica: inflammation suppression with low dose of methylprednisolone or modified-release prednisone.
Benucci M; Olivito B; Manfredi M; Meacci F; Infantino M; Li Gobbi F; Sarzi-Puttini P; Marcassa C; Atzeni F
Eur Rev Med Pharmacol Sci; 2015; 19(5):745-51. PubMed ID: 25807425
[TBL] [Abstract][Full Text] [Related]
2. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis.
Sulli A; Montecucco CM; Caporali R; Cavagna L; Montagna P; Capellino S; Fazzuoli L; Seriolo B; Alessandro C; Secchi ME; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():307-14. PubMed ID: 16855158
[TBL] [Abstract][Full Text] [Related]
4. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica.
Dasgupta B; Dolan AL; Panayi GS; Fernandes L
Br J Rheumatol; 1998 Feb; 37(2):189-95. PubMed ID: 9569075
[TBL] [Abstract][Full Text] [Related]
5. Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study.
Galbo H; Kall L
Arthritis Res Ther; 2016 Jul; 18(1):174. PubMed ID: 27455959
[TBL] [Abstract][Full Text] [Related]
6. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
7. Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study.
Miceli MC; Zoli A; Peluso G; Bosello S; Gremese E; Ferraccioli G
J Rheumatol; 2017 Feb; 44(2):241-247. PubMed ID: 27980012
[TBL] [Abstract][Full Text] [Related]
8. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable.
Devauchelle-Pensec V; Saraux L; Berthelot JM; De Bandt M; Cornec D; Guellec D; Marhadour T; Jousse-Joulin S; Gouillou M; Saraux A
Rheumatology (Oxford); 2018 Apr; 57(4):666-670. PubMed ID: 29346621
[TBL] [Abstract][Full Text] [Related]
9. Contribution of the polymyalgia rheumatica activity score to glucocorticoid dosage adjustment in everyday practice.
Cleuziou C; Binard A; De Bandt M; Berthelot JM; Saraux A
J Rheumatol; 2012 Feb; 39(2):310-3. PubMed ID: 22174199
[TBL] [Abstract][Full Text] [Related]
10. Prednisone compared to methylprednisolone in the polymyalgia rheumatica treatment.
Viapiana O; Gatti D; Troplini S; Adami S; Fracassi E; Idolazzi L; Rossini M
Rheumatol Int; 2015 Apr; 35(4):735-9. PubMed ID: 25149179
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis.
Cutolo M; Montecucco CM; Cavagna L; Caporali R; Capellino S; Montagna P; Fazzuoli L; Villaggio B; Seriolo B; Sulli A
Ann Rheum Dis; 2006 Nov; 65(11):1438-43. PubMed ID: 16644782
[TBL] [Abstract][Full Text] [Related]
12. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.
Dolan AL; Moniz C; Dasgupta B; Li F; Mackintosh C; Todd P; Corrigall V; Panayi GS
Arthritis Rheum; 1997 Nov; 40(11):2022-9. PubMed ID: 9365092
[TBL] [Abstract][Full Text] [Related]
13. Deflazacort versus methylprednisolone in polymyalgia rheumatica: clinical equivalence and relative antiinflammatory potency of different treatment regimens.
Di Munno O; Imbimbo B; Mazzantini M; Milani S; Occhipinti G; Pasero G
J Rheumatol; 1995 Aug; 22(8):1492-8. PubMed ID: 7473472
[TBL] [Abstract][Full Text] [Related]
14. Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates.
Giollo A; Rossini M; Bettili F; Ghellere F; Fracassi E; Idolazzi L; Gatti D; Viapiana O
J Rheumatol; 2019 Mar; 46(3):318-322. PubMed ID: 30385701
[TBL] [Abstract][Full Text] [Related]
15. Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica.
Cimmino MA; Andraghetti G; Briatore L; Salani B; Parodi M; Cutolo M; Cordera R
Ann N Y Acad Sci; 2010 Apr; 1193():160-3. PubMed ID: 20398023
[TBL] [Abstract][Full Text] [Related]
16. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study.
Cutolo M; Hopp M; Liebscher S; Dasgupta B; Buttgereit F
RMD Open; 2017; 3(1):e000426. PubMed ID: 28405475
[TBL] [Abstract][Full Text] [Related]
17. The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.
Cimmino MA; Parodi M; Montecucco C; Caporali R
BMC Musculoskelet Disord; 2011 May; 12(1):94. PubMed ID: 21569559
[TBL] [Abstract][Full Text] [Related]
18. In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers.
Straub RH; Georgi J; Helmke K; Vaith P; Lang B
Rheumatology (Oxford); 2002 Apr; 41(4):423-9. PubMed ID: 11961173
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica.
Muratore F; Salvarani C; Macchioni P
Reumatismo; 2018 Mar; 70(1):18-22. PubMed ID: 29589399
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica.
Lally L; Forbess L; Hatzis C; Spiera R
Arthritis Rheumatol; 2016 Oct; 68(10):2550-4. PubMed ID: 27159185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
